Senti Biosciences Holdings, Inc.
About Senti Biosciences Holdings, Inc.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $22.0K
- Net income
- -$61.4M
- Total assets
- $51.2M
- Market cap
- $30.1M
- Operating margin
- -312631.8%
- Net margin
- -279263.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $22.0K
- Operating expenses
- $68.8M
- Operating income
- -$68.8M
- Income tax
- $0
- Net income
- -$61.4M
- EPS (basic)
- $-2.73
- EPS (diluted)
- $-2.73
Balance sheet
- Total assets
- $51.2M
- Current assets
- $23.3M
- Total liabilities
- $45.6M
- Current liabilities
- $14.0M
- Shareholders’ equity
- $5.6M
Cash flow
- Operating cash flow
- -$43.4M
- Investing cash flow
- -$184.0K
- Financing cash flow
- $11.8M
- Net cash flow
- -$31.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $30.1M
- EPS (diluted)
- $-2.73
- Shares outstanding
- 32.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 9, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $61.4M in FY2025.
- Revenue declined 99% from FY2022 to FY2025.
- Trading 76% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Senti Biosciences Holdings, Inc..
Write a review
News about Senti Biosciences Holdings, Inc.
News & sentiment via Polygon.io
